Enrollment data

All stockholders should message management with a strong request to release enrollment data and other useful information via a press release ASAP. Regeneron's failure is bad for Covid patients, but an opportunity for CYDY; but only if the enrollment is such that the trial can be finished within a reasonable period of time. Bullish investors will raise the stock price. However, without critical information, nothing's new here. And the SP will continue to drift- usually downward.